INTS Key Statistics, Chart & Performance
The current stock price of INTS is 0.47 USD. In the past month the price decreased by -1.69%. In the past year, price decreased by -77.18%.
INTS Latest News, Press Relases and Analysis
INTS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About INTS
Company Profile
Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. The company is headquartered in Shelton, Connecticut and currently employs 5 full-time employees. The company went IPO on 2023-06-30. The company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
Company Info
INTENSITY THERAPEUTICS INC
1 Enterprise Drive, Suite 430
Shelton CONNECTICUT US
Employees: 6
Phone: 12032217381
INTENSITY THERAPEUTICS INC / INTS FAQ
What does INTS do?
Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. The company is headquartered in Shelton, Connecticut and currently employs 5 full-time employees. The company went IPO on 2023-06-30. The company is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.
What is the stock price of INTENSITY THERAPEUTICS INC today?
The current stock price of INTS is 0.47 USD. The price decreased by -20.34% in the last trading session.
Does INTENSITY THERAPEUTICS INC pay dividends?
INTS does not pay a dividend.
What is the ChartMill technical and fundamental rating of INTS stock?
INTS has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is INTS stock listed?
INTS stock is listed on the Nasdaq exchange.
How is the market expecting INTS stock to perform?
12 analysts have analysed INTS and the average price target is 2.98 USD. This implies a price increase of 532.99% is expected in the next year compared to the current price of 0.47.
Can you provide the ownership details for INTS stock?
You can find the ownership structure of INTENSITY THERAPEUTICS INC (INTS) on the Ownership tab.
INTS Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to INTS. When comparing the yearly performance of all stocks, INTS is one of the better performing stocks in the market, outperforming 77.55% of all stocks.
INTS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to INTS. While INTS seems to be doing ok healthwise, there are quite some concerns on its profitability.
INTS Financial Highlights
Over the last trailing twelve months INTS reported a non-GAAP Earnings per Share(EPS) of -0.63. The EPS increased by 41.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -122.44% | ||
| ROE | -162.5% | ||
| Debt/Equity | 0 |
INTS Forecast & Estimates
12 analysts have analysed INTS and the average price target is 2.98 USD. This implies a price increase of 532.99% is expected in the next year compared to the current price of 0.47.